Pediatrix Medical Group Inc Dossier
|
SectorHealth Care IndustryMedical Care Facilities Beta (adjusted)0.77 Intrinsic Value $23.21median of 6 methods · middle span $15-$49based on filings through 30 Jun 2026 Market Price $25.76Price as of 1 Oct 2026 Near fair valueIntrinsic value is 10% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $2.1B Enterprise Value $2.4B Shares Outstanding 82M diluted Moat Rating Wide Next Earnings Date2 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Pediatrix Medical Group, Inc. (NYSE: MD) is demonstrating solid operational resilience under the returned leadership of CEO Mark S. Ordan. The company's strategic refocus on its core, higher-margin neonatal, maternal-fetal, and pediatric subspecialty services is yielding positive results, as evidenced by a strong Q1 2026 earnings beat. However, persistent headwinds including modest volume declines (such as a 1% drop in NICU days), ongoing labor shortages, and potential shifts in payer mix warrant a cautious near-term outlook. While the company's balance sheet remains healthy with low leverage (1.3x net debt to EBITDA) and robust cash flow, limited top-line visibility and contract renegotiation risks keep the stock range-bound, making a Hold recommendation appropriate at current valuation levels. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$21.00 Mean target$26.17 High · most bullish analyst$28.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Labor shortages intensify, forcing higher reliance on expensive contract labor and premium pay. Medicaid redeterminations or the lapse of healthcare subsidies unfavorably shift the payer mix toward government programs, compressing margins. Contract renegotiations with key hospital partners stall, causing same-unit revenue growth to turn negative and dragging Adjusted EBITDA below the guided $280 million floor. Base CaseCentral scenario The company successfully executes its portfolio restructuring, focusing capital on high-acuity neonatal and maternal-fetal care. Pricing growth of ~4% driven by improved revenue cycle management and hospital administrative fees offsets modest volume declines of 1-2%. Adjusted EBITDA lands within the guided range of $280 million to $300 million for FY2026, maintaining stable leverage and supporting technical consolidation near current levels. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |